Label Comprehension Guidance May Improve Switch Outlook
This article was originally published in The Tan Sheet
Executive Summary
Final guidance for label comprehension studies replaces several draconian draft recommendations with more flexible "common sense" measures, but drug sponsors may need to conduct significantly larger, more expensive studies and meet more extensively with the agency, experts say
You may also be interested in...
Outpatient Rx Safety Meeting To Spotlight Health Literacy, Provider Communication
US FDA has made efforts to improve health communications to cater to deficiencies in literacy; other specific topics for discussion at the meeting remain unclear.
In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers
Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.
In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers
Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.